Autoimmune disease

Immunovant announced positive six-month remission data for batoclimab in uncontrolled Graves’ disease. ~80% of patients (17/21) maintained normal thyroid function after stopping treatment, with ~50% (8/17) achieving complete remission without anti-thyroid drugs. Another 30% needed only minimal doses. IMVT-1402, is being evaluated in two trials with results expected in 2027. This therapy targets the autoimmune root of Graves’ disease by blocking FcRn. If successful, this could significantly improve treatment for Graves’ disease patients.

Novartis announced positive top-line results from Phase III trials (NEPTUNUS-1 and NEPTUNUS-2) evaluating ianalumab (VAY736) in Sjögren’s disease. Both trials met the primary endpoint, showing statistically significant reduction in disease activity. Ianalumab, with its dual mechanism, is poised to potentially be the first targeted treatment for this autoimmune condition. The drug demonstrated a favorable safety profile and will be submitted to global health authorities.